NMDA receptor modulation and severe acute respiratory syndrome treatment
Copyright: © 2021 Costa BM..
N-Methyl-D-aspartate (NMDA) subtype of glutamate receptors is expressed in the human lungs and central nervous system. NMDA receptor potentiation could increase calcium ion influx and promote downstream signaling mechanisms associated with cellular contractions that are disrupted in severe acute respiratory syndrome. Pharmacological effects generated by triggering glutamate receptor function in the brain, coupled with concurrent stimulation of the respiratory tract, may produce a synergetic effect, improving the airway smooth muscle function. A novel multipronged intervention to simultaneously potentiate NMDA receptors expressed both in the central nervous system and airway muscles would be helpful for the treatment of severe acute respiratory syndrome that deteriorates peripheral and central nervous system function before causing death in humans.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
F1000Research - 10(2021) vom: 12. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Costa, Blaise M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3KX376GY7L |
|---|
| Anmerkungen: |
Date Completed 25.01.2023 Date Revised 25.01.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.12688/f1000research.73897.1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350561346 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350561346 | ||
| 003 | DE-627 | ||
| 005 | 20231226045258.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.12688/f1000research.73897.1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350561346 | ||
| 035 | |a (NLM)36544563 | ||
| 035 | |a (PII)Chem Inf Sci-1060 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Costa, Blaise M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NMDA receptor modulation and severe acute respiratory syndrome treatment |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2023 | ||
| 500 | |a Date Revised 25.01.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright: © 2021 Costa BM. | ||
| 520 | |a N-Methyl-D-aspartate (NMDA) subtype of glutamate receptors is expressed in the human lungs and central nervous system. NMDA receptor potentiation could increase calcium ion influx and promote downstream signaling mechanisms associated with cellular contractions that are disrupted in severe acute respiratory syndrome. Pharmacological effects generated by triggering glutamate receptor function in the brain, coupled with concurrent stimulation of the respiratory tract, may produce a synergetic effect, improving the airway smooth muscle function. A novel multipronged intervention to simultaneously potentiate NMDA receptors expressed both in the central nervous system and airway muscles would be helpful for the treatment of severe acute respiratory syndrome that deteriorates peripheral and central nervous system function before causing death in humans | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a GluN2D | |
| 650 | 4 | |a NMDA | |
| 650 | 4 | |a Potentiator | |
| 650 | 4 | |a severe respiratory syndrome (SARS) | |
| 650 | 7 | |a Glutamic Acid |2 NLM | |
| 650 | 7 | |a 3KX376GY7L |2 NLM | |
| 650 | 7 | |a Receptors, N-Methyl-D-Aspartate |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t F1000Research |d 2012 |g 10(2021) vom: 12. |w (DE-627)NLM22994549X |x 2046-1402 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g day:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.12688/f1000research.73897.1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |b 12 | ||